Pemvidutide alcohol use disorder data reach AASLD before FDA Phase 3 talks

The first full look at pemvidutide alcohol use disorder data will come as a late-breaking oral talk at the AASLD liver congress in Denver on 9 November 2026, Altimmune said on 5 November. The company also said it will meet the FDA in December to discuss a Phase 3 program. The molecule stays at Phase 2 for this use on our board, because the headline efficacy numbers came out in July and the talk adds detail, not a new stage.

What Altimmune announced this week

The American Association for the Study of Liver Diseases accepted a late-breaking abstract on RECLAIM for an oral slot at The Liver Meeting 2026, which runs from 5 to 9 November in Denver, according to the Altimmune announcement. The talk sits in Late-Breaker Session 3 on Monday 9 November at 10:30 a.m. Mountain Time. Henry R. Kranzler, a psychiatry professor who directs the Center for Studies of Addiction at the University of Pennsylvania, will present it. He was also the trial's principal investigator, according to the company's July release. Altimmune said the slides will go up on its website once the session ends. Organizers keep late-breaking slots for important findings from large prospective studies that missed the regular deadline, so selection reflects reviewer interest, not a verdict on the drug.

The second item in the release matters more for the pipeline. Altimmune said it is scheduled to hold an End of Phase 2 meeting with the FDA in December to discuss a registrational Phase 3 program in alcohol use disorder. In July the company had only said it planned to request that meeting, so a date on the calendar is a small step forward. It is not a stage change. At this kind of meeting, a sponsor and the agency talk through trial design, endpoints and size before pivotal studies begin. The FDA does not usually publish what was agreed, so readers will depend on the company's own account. Pemvidutide already holds Fast Track designation for alcohol use disorder, as well as for MASH, the company said.

What the RECLAIM Phase 2 trial showed in July

The RECLAIM Phase 2 trial randomized about 100 adults with moderate to severe alcohol use disorder and a body mass index above 25 to weekly pemvidutide or placebo for 24 weeks. The drug arm used one fixed dose, reached after a short titration. In the topline results filed with the SEC on 28 July, heavy drinking days per week fell by a least squares mean of 4.20 on drug and 2.75 on placebo, a statistically significant gap with a p value of 0.0014. Placebo patients also cut their heavy drinking by almost three days a week, so the drug's added effect was about one and a half days. Two outcomes the company says the FDA recognizes as registrational endpoints also favored the drug.

Placebo patients also cut their heavy drinking by almost three days a week, so the drug's added effect was about one and a half days.

On those two measures, 64.4% on pemvidutide versus 34.8% on placebo dropped two World Health Organization risk drinking levels, and 42.2% versus 17.4% reported no heavy drinking days in weeks 21 to 24. Phosphatidylethanol, a blood marker of recent alcohol intake, fell sharply on drug and rose slightly on placebo, which supports the diary based counts. Body weight fell 9.1% more than on placebo, an effect that fits a glucagon GLP-1 dual agonist in a trial that enrolled only people with overweight or obesity. The efficacy analyses counted 45 drug and 46 placebo patients, while 50 per arm received treatment. These are company figures, and the full pemvidutide alcohol use disorder dataset and a peer reviewed paper have not yet appeared.

Side effects and the limits of a 24 week study

Gastrointestinal effects were the main cost. Nausea affected 44% of patients on pemvidutide against 24% on placebo, vomiting 18% against 6%, constipation 26% against 6% and diarrhea 20% against 10%. Five people on drug, or 10%, stopped because of side effects judged related to treatment, compared with none on placebo, while overall dropout was similar in both arms at about one in five. Serious adverse events were rare, two on drug and one on placebo, and the company said one case of low blood sodium on drug was judged possibly related by the investigator. Altimmune describes tolerability as generally favorable and says most events were mild to moderate. Those are the sponsor's words, and the full safety tables in Denver should show more.

Several questions about the pemvidutide alcohol use disorder program stay open. RECLAIM tested one dose for six months, so it says nothing about longer use, drinking after treatment stops, or the best dose. It enrolled only people with a body mass index above 25, which leaves out leaner drinkers, and it is not yet known whether a Phase 3 program would include them. Most drinking outcomes rest on self report, though the blood marker helps. The trial had no active comparator, so it cannot show how the drug compares with the three medicines the FDA has approved for the disorder, which Altimmune says fewer than 2% of patients use. About 100 people is also a small sample for a condition the company says affects about 12 million US adults in moderate or severe form.

Where GLP 1 drugs for alcohol stand now

Interest in GLP-1 drugs for alcohol has run ahead of controlled data. A national survey we covered this week found that many adults starting a GLP-1 medicine said they drank less, but self reported drinking changes in a survey cannot prove the drug caused them. According to Altimmune, RECLAIM is the first multicenter Phase 2 trial of a dual glucagon and GLP-1 agonist in alcohol use disorder to report results. The company argues that the glucagon component adds a direct effect on the liver, which matters because heavy drinking damages that organ. The idea is plausible but untested here, because RECLAIM did not compare pemvidutide with a drug that acts on GLP-1 alone.

Alcohol is one of three lanes for the molecule. In MASH, the fatty liver disease tied to metabolic health, Altimmune started the PERFORMA Phase 3 trial in July 2026 after reporting 48 week IMPACT Phase 2b data in December 2025. The earlier IMPACT readout in June 2025 cleared liver inflammation but missed on liver scarring, a reminder that one strong endpoint does not settle a program. A third Phase 2 trial, RESTORE, finished enrollment in alcohol associated liver disease in August 2026. On the incretin molecules board, pemvidutide stays at Phase 2 for alcohol use disorder. A move to Phase 3 needs an agreed design after December and a first patient dosed, and the company has not given a start date.

Conclusion

The 9 November talk will put fuller pemvidutide alcohol use disorder data in front of liver specialists, but the headline numbers have been public since July. The checkpoint that can move the molecule is the December meeting with the FDA and what Altimmune then says about Phase 3 size, endpoints and timing. Until a pivotal trial starts, the board keeps pemvidutide at Phase 2 for this use with a flat signal. This is research reporting, not medical advice.